

James A Mccubrey

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/491618/publications.pdf](https://exaly.com/author-pdf/491618/publications.pdf)

Version: 2024-02-01

287
papers

20,623
citations

14509

65
h-index

14407

126
g-index

351
all docs

351
docs citations

351
times ranked

29151
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of chloroquine and hydroxychloroquine on the sensitivity of pancreatic cancer cells to targeted therapies. <i>Advances in Biological Regulation</i> , 2023, 87, 100917.	2.7	1
2	Understanding the Roles of the Hedgehog Signaling Pathway during T-Cell Lymphopoiesis and in T-Cell Acute Lymphoblastic Leukemia (T-ALL). <i>International Journal of Molecular Sciences</i> , 2023, 24, 2962.	4.2	6
3	Phospholipases in Gliomas: Current Knowledge and Future Perspectives from Bench to Bedside. <i>Biomolecules</i> , 2023, 13, 798.	4.1	0
4	The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19. <i>Drug Discovery Today</i> , 2022, 27, 848-856.	6.6	57
5	Role of PLC β 3 in the modulation of cell migration and cell invasion in glioblastoma. <i>Advances in Biological Regulation</i> , 2022, 83, 100838.	2.7	5
6	Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53. <i>Advances in Biological Regulation</i> , 2022, 83, 100840.	2.7	6
7	APR-246 "The Mutant TP53 Reactivator" Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells. <i>Biomolecules</i> , 2022, 12, 276.	4.1	5
8	Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53. <i>Cells</i> , 2022, 11, 794.	4.2	7
9	Phytol and Heptacosane Are Possible Tools to Overcome Multidrug Resistance in an In Vitro Model of Acute Myeloid Leukemia. <i>Pharmaceuticals</i> , 2022, 15, 356.	3.9	11
10	Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties. <i>Aging</i> , 2022, 14, 3365-3386.	2.8	5
11	Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies. <i>Cells</i> , 2022, 11, 1812.	4.2	5
12	Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression. <i>Cells</i> , 2022, 11, 2155.	4.2	20
13	Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53. <i>Advances in Biological Regulation</i> , 2021, 79, 100780.	2.7	6
14	Recent Progress in Discovering the Role of Carotenoids and Metabolites in Prostatic Physiology and Pathology "A Review" Part II: Carotenoids in the Human Studies. <i>Antioxidants</i> , 2021, 10, 319.	5.2	15
15	Recent Progress in Discovering the Role of Carotenoids and Their Metabolites in Prostatic Physiology and Pathology with a Focus on Prostate Cancer "A Review" Part I: Molecular Mechanisms of Carotenoid Action. <i>Antioxidants</i> , 2021, 10, 585.	5.2	17
16	GSK-3 β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. <i>Cells</i> , 2021, 10, 816.	4.2	19
17	GSK-3: a multifaceted player in acute leukemias. <i>Leukemia</i> , 2021, 35, 1829-1842.	7.4	24
18	GSK3 as a Regulator of Cytoskeleton Architecture: Consequences for Health and Disease. <i>Cells</i> , 2021, 10, 2092.	4.2	22

#	ARTICLE	IF	CITATIONS
19	Lamin B1 Accumulation's Effects on Autosomal Dominant Leukodystrophy (ADLD): Induction of Reactivity in the Astrocytes. <i>Cells</i> , 2021, 10, 2566.	4.2	5
20	The NUPR1/p73 axis contributes to sorafenib resistance in hepatocellular carcinoma. <i>Cancer Letters</i> , 2021, 519, 250-262.	7.3	9
21	Location-dependent role of phospholipase C signaling in the brain: Physiology and pathology. <i>Advances in Biological Regulation</i> , 2021, 79, 100771.	2.7	19
22	Recent advances in MDS mutation landscape: Splicing and signalling. <i>Advances in Biological Regulation</i> , 2020, 75, 100673.	2.7	7
23	Abilities of 17β -Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells. <i>Advances in Biological Regulation</i> , 2020, 75, 100672.	2.7	10
24	Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling. <i>Advances in Biological Regulation</i> , 2020, 78, 100758.	2.7	24
25	Where are we with understanding of COVID-19?. <i>Advances in Biological Regulation</i> , 2020, 77, 100745.	2.7	6
26	Subcellular Localization Relevance and Cancer-Associated Mechanisms of Diacylglycerol Kinases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5297.	4.2	15
27	Cancer therapy and treatments during COVID-19 era. <i>Advances in Biological Regulation</i> , 2020, 77, 100739.	2.7	31
28	Phospholipase C beta1 (PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS). <i>FASEB Journal</i> , 2020, 34, 15400-15416.	0.4	6
29	Targeting GSK3 and Associated Signaling Pathways Involved in Cancer. <i>Cells</i> , 2020, 9, 1110.	4.2	163
30	The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment. <i>Cells</i> , 2020, 9, 1427.	4.2	54
31	GSK-3 and miRs: Master regulators of therapeutic sensitivity of cancer cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2020, 1867, 118770.	4.1	10
32	Where are we with understanding of COVID-19?. <i>Advances in Biological Regulation</i> , 2020, 78, 100738.	2.7	8
33	GSK3 and miRNA in neural tissue: From brain development to neurodegenerative diseases. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2020, 1867, 118696.	4.1	16
34	GSK-3-associated signaling is crucial to virus infection of cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2020, 1867, 118767.	4.1	11
35	Foreword for the special issue advances in COVID-19: Biology and clinic. <i>Advances in Biological Regulation</i> , 2020, 77, 100744.	2.7	0
36	The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias. <i>Cancers</i> , 2020, 12, 333.	3.8	30

#	ARTICLE	IF	CITATIONS
37	The Reverse Warburg Effect Is Associated with Fbp2-Dependent Hif1 α Regulation in Cancer Cells Stimulated by Fibroblasts. <i>Cells</i> , 2020, 9, 205.	4.2	18
38	Cell-to-cell lactate shuttle operates in heart and is important in age-related heart failure. <i>Aging</i> , 2020, 12, 3388-3406.	2.8	19
39	GSK-3 in liver diseases: Friend or foe?. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2020, 1867, 118743.	4.1	15
40	RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 915-929.	3.4	64
41	Antitumor Mechanism of the Essential Oils from Two Succulent Plants in Multidrug Resistance Leukemia Cell. <i>Pharmaceuticals</i> , 2019, 12, 124.	3.9	9
42	The Key Roles of PTEN in T-Cell Acute Lymphoblastic Leukemia Development, Progression, and Therapeutic Response. <i>Cancers</i> , 2019, 11, 629.	3.8	33
43	Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells. <i>Advances in Biological Regulation</i> , 2019, 73, 100633.	2.7	25
44	Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2019, 1866, 1322-1337.	4.1	21
45	Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals. <i>Advances in Biological Regulation</i> , 2019, 72, 22-40.	2.7	11
46	miRNAs and their roles in KSHV pathogenesis. <i>Virus Research</i> , 2019, 266, 15-24.	2.3	17
47	Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes. <i>Leukemia</i> , 2019, 33, 2276-2290.	7.4	25
48	Inositide-Dependent Nuclear Signalling in Health and Disease. <i>Handbook of Experimental Pharmacology</i> , 2019, 259, 291-308.	1.0	5
49	Clusterin enhances AKT α -mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit. <i>Journal of Cellular Physiology</i> , 2019, 234, 11188-11199.	4.1	20
50	Phospholipase C- β 2 interacts with cyclin E in adipose- derived stem cells osteogenic differentiation. <i>Advances in Biological Regulation</i> , 2019, 71, 1-9.	2.7	18
51	Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells. <i>Advances in Biological Regulation</i> , 2019, 71, 172-182.	2.7	34
52	Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2019, 144, 2613-2624.	5.4	41
53	Nuclear phospholipase C isoenzyme imbalance leads to pathologies in brain, hematologic, neuromuscular, and fertility disorders. <i>Journal of Lipid Research</i> , 2019, 60, 312-317.	4.2	28
54	Metformin influences drug sensitivity in pancreatic cancer cells. <i>Advances in Biological Regulation</i> , 2018, 68, 13-30.	2.7	46

#	ARTICLE	IF	CITATIONS
55	Drug discovery targeting the mTOR pathway. <i>Clinical Science</i> , 2018, 132, 543-568.	4.3	66
56	Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update. <i>Journal of Cellular Physiology</i> , 2018, 233, 6440-6454.	4.1	38
57	Current therapy and new drugs: a road to personalized treatment of myelodysplastic syndromes. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 23-31.	0.6	1
58	Cutaneous melanoma: From pathogenesis to therapy (Review). <i>International Journal of Oncology</i> , 2018, 52, 1071-1080.	3.1	304
59	Nuclear translocation of PKC ζ is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs). <i>FASEB Journal</i> , 2018, 32, 681-692.	0.4	24
60	Effects of berberine, curcumin, resveratrol alone and in combination with chemotherapeutic drugs and signal transduction inhibitors on cancer cells—Power of nutraceuticals. <i>Advances in Biological Regulation</i> , 2018, 67, 190-211.	2.7	25
61	Nuclear inositide signaling and cell cycle. <i>Advances in Biological Regulation</i> , 2018, 67, 1-6.	2.7	31
62	Cardiovascular disease-related miRNAs expression: potential role as biomarkers and effects of training exercise. <i>Oncotarget</i> , 2018, 9, 17238-17254.	1.9	54
63	Impact of physical exercise in cancer survivors during and after antineoplastic treatments. <i>Oncotarget</i> , 2018, 9, 14005-14034.	1.9	75
64	NOTCH3 expression is linked to breast cancer seeding and distant metastasis. <i>Breast Cancer Research</i> , 2018, 20, 105.	5.1	61
65	Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis. <i>Oncotarget</i> , 2018, 9, 8263-8277.	1.9	77
66	Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals. <i>Advances in Biological Regulation</i> , 2018, 69, 16-34.	2.7	28
67	Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1878.	4.2	38
68	Roles of p53, NF- κ B and the androgen receptor in controlling NGAL expression in prostate cancer cell lines. <i>Advances in Biological Regulation</i> , 2018, 69, 43-62.	2.7	21
69	Influence of physical exercise on microRNAs in skeletal muscle regeneration, aging and diseases. <i>Oncotarget</i> , 2018, 9, 17220-17237.	1.9	45
70	Nuclear Inositide Signaling Via Phospholipase C. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 1969-1978.	2.6	30
71	PLC- δ 1 and cell differentiation: An insight into myogenesis and osteogenesis. <i>Advances in Biological Regulation</i> , 2017, 63, 1-5.	2.7	36
72	PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. <i>Scientific Reports</i> , 2017, 7, 43013.	3.4	44

#	ARTICLE	IF	CITATIONS
73	Pivotal roles of glycogen synthase-3 in hepatocellular carcinoma. <i>Advances in Biological Regulation</i> , 2017, 65, 59-76.	2.7	40
74	Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases. <i>Advances in Biological Regulation</i> , 2017, 65, 77-88.	2.7	40
75	GSK-3 signaling in health. <i>Advances in Biological Regulation</i> , 2017, 65, 1-4.	2.7	9
76	HIV protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives?. <i>International Journal of Cancer</i> , 2017, 140, 1713-1726.	5.4	65
77	Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis. <i>Advances in Biological Regulation</i> , 2017, 63, 32-48.	2.7	38
78	Dimeric and tetrameric forms of muscle fructose-1,6-bisphosphatase play different roles in the cell. <i>Oncotarget</i> , 2017, 8, 115420-115433.	1.9	14
79	Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells. <i>Oncotarget</i> , 2017, 8, 91803-91816.	1.9	23
80	Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs. <i>Aging</i> , 2017, 9, 1477-1536.	2.8	180
81	Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells. <i>Oncotarget</i> , 2017, 8, 14221-14250.	1.9	87
82	PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines. <i>Oncotarget</i> , 2017, 8, 23213-23227.	1.9	15
83	Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells. <i>Oncotarget</i> , 2017, 8, 76525-76557.	1.9	17
84	Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDRI, drug efflux and side-population positive and decreased BCL2-family member expression. <i>Oncotarget</i> , 2017, 8, 113013-113033.	1.9	8
85	Oleocanthol exerts antitumor effects on human liver and colon cancer cells through ROS generation. <i>International Journal of Oncology</i> , 2017, 51, 533-544.	3.1	74
86	Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer. <i>PLoS ONE</i> , 2016, 11, e0152104.	2.5	54
87	MMP-9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma. <i>Aging</i> , 2016, 8, 933-944.	2.8	70
88	Effects of mutations in Wnt/ β -catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity—Diverse effects on cell growth, metabolism and cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 2942-2976.	4.1	139
89	Nuclear Phosphatidylinositol Signaling: Focus on Phosphatidylinositol Phosphate Kinases and Phospholipases C. <i>Journal of Cellular Physiology</i> , 2016, 231, 1645-1655.	4.1	52
90	Diagnostic value of neutrophil gelatinase-associated lipocalin/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder. <i>Tumor Biology</i> , 2016, 37, 9855-9863.	1.7	16

#	ARTICLE	IF	CITATIONS
91	Tumor microenvironment in diffuse large B-cell lymphoma: Matrixmetalloproteinases activation is mediated by osteopontin overexpression. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 483-489.	4.1	30
92	Modulation of nuclear PI-PLCbeta1 during cell differentiation. <i>Advances in Biological Regulation</i> , 2016, 60, 1-5.	2.7	25
93	Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 677-687.	3.4	13
94	Novel roles of androgen receptor, epidermal growth factor receptor, TP53, regulatory RNAs, NF-kappa-B, chromosomal translocations, neutrophil associated gelatinase, and matrix metalloproteinase-9 in prostate cancer and prostate cancer stem cells. <i>Advances in Biological Regulation</i> , 2016, 60, 64-87.	2.7	35
95	Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 449-463.	4.1	111
96	Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 438-448.	4.1	79
97	Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia. <i>Oncotarget</i> , 2016, 7, 55690-55703.	1.9	15
98	Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer. <i>Oncotarget</i> , 2016, 7, 72758-72766.	1.9	73
99	Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia. <i>Oncotarget</i> , 2016, 7, 79842-79853.	1.9	23
100	Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF- κ B. <i>Oncotarget</i> , 2016, 7, 1323-1340.	1.9	39
101	Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation. <i>Current Pharmaceutical Design</i> , 2016, 22, 2345-2348.	1.8	22
102	Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy. <i>Current Pharmaceutical Design</i> , 2016, 22, 2358-2388.	1.8	34
103	Raf/MEK/ERK Signaling. , 2015, , 275-305.		0
104	Malignant melanoma in elderly patients: biological, surgical and medical issues. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 101-108.	2.5	28
105	Current treatment strategies for inhibiting mTOR in cancer. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 124-135.	8.6	237
106	Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells. <i>Advances in Biological Regulation</i> , 2015, 59, 65-81.	2.7	125
107	The NO-modified HIV protease inhibitor as a valuable drug for hematological malignancies: Role of p70S6K. <i>Leukemia Research</i> , 2015, 39, 1088-1095.	1.1	25
108	PLC and PI3K/Akt/mTOR signalling in disease and cancer. <i>Advances in Biological Regulation</i> , 2015, 57, 10-16.	2.7	113

#	ARTICLE	IF	CITATIONS
109	Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis. <i>Advances in Biological Regulation</i> , 2015, 57, 75-101.	2.7	102
110	Autophagy in acute leukemias: A double-edged sword with important therapeutic implications. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015, 1853, 14-26.	4.1	76
111	Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells. <i>Oncotarget</i> , 2015, 6, 1707-1722.	1.9	31
112	Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia. <i>Oncotarget</i> , 2015, 6, 6597-6610.	1.9	28
113	PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. <i>Oncotarget</i> , 2015, 6, 10399-10414.	1.9	32
114	Quantitative phosphoproteome analysis of embryonic stem cell differentiation toward blood. <i>Oncotarget</i> , 2015, 6, 10924-10939.	1.9	7
115	The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells. <i>Oncotarget</i> , 2015, 6, 17147-17160.	1.9	31
116	Insulin/IGF1-PI3K-dependent nucleolar localization of a glycolytic enzyme - phosphoglycerate mutase 2, is necessary for proper structure of nucleolus and RNA synthesis. <i>Oncotarget</i> , 2015, 6, 17237-17250.	1.9	10
117	Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. <i>Oncotarget</i> , 2015, 6, 32089-32103.	1.9	36
118	Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. <i>Oncotarget</i> , 2014, 5, 1576-1594.	1.9	92
119	Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. <i>Oncotarget</i> , 2014, 5, 4603-4650.	1.9	239
120	GSK-3 as potential target for therapeutic intervention in cancer. <i>Oncotarget</i> , 2014, 5, 2881-2911.	1.9	419
121	Diverse roles of GSK-3: Tumor promoter/tumor suppressor, target in cancer therapy. <i>Advances in Biological Regulation</i> , 2014, 54, 176-196.	2.7	82
122	Foreword: Targeting signaling pathways in stem cells. <i>Advances in Biological Regulation</i> , 2014, 56, 1-5.	2.7	4
123	Nuclear PI-PLC β 1: An appraisal on targets and pathology. <i>Advances in Biological Regulation</i> , 2014, 54, 2-11.	2.7	33
124	Targeting breast cancer initiating cells: Advances in breast cancer research and therapy. <i>Advances in Biological Regulation</i> , 2014, 56, 81-107.	2.7	33
125	NOTCH and PTEN in prostate cancer. <i>Advances in Biological Regulation</i> , 2014, 56, 51-65.	2.7	45
126	Pancreatic cancer stem cells: Association with cell surface markers, prognosis, resistance, metastasis and treatment. <i>Advances in Biological Regulation</i> , 2014, 56, 45-50.	2.7	85

#	ARTICLE	IF	CITATIONS
127	Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (Review). International Journal of Oncology, 2014, 45, 909-918.	3.1	21
128	Analysis of the B-RAFV600E mutation in cutaneous melanoma patients with occupational sun exposure. Oncology Reports, 2014, 31, 1079-1082.	2.6	47
129	Emerging targeted therapies for melanoma treatment (Review). International Journal of Oncology, 2014, 45, 516-524.	3.1	39
130	Inhibition of Cdk2 kinase activity selectively targets the CD44+/CD24 ^{low} /Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells. International Journal of Oncology, 2014, 45, 1193-1199.	3.1	45
131	Aurora-A Mitotic Kinase Induces Endocrine Resistance through Down-Regulation of ER α Expression in Initially ER α + Breast Cancer Cells. PLoS ONE, 2014, 9, e96995.	2.5	31
132	PLC-beta 1 regulates the expression of miR-210 during mithramycin-mediated erythroid differentiation in K562 cells. Oncotarget, 2014, 5, 4222-4231.	1.9	19
133	Assessment of the effect of sphingosine kinase inhibitors on apoptosis, unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics. Oncotarget, 2014, 5, 7886-7901.	1.9	36
134	Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. Oncotarget, 2014, 5, 10034-10047.	1.9	63
135	A novel DAG-dependent mechanism links PKCa and Cyclin B1 regulating cell cycle progression. Oncotarget, 2014, 5, 11526-11540.	1.9	18
136	Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLC. Current Pharmaceutical Design, 2014, 20, 3944-3957.	1.8	57
137	From Targets to Targeted Therapies in Hepatocellular Carcinoma. Onco Therapeutics, 2014, 5, 145-194.	0.2	1
138	Comparative Study of Rapamycin and Temsirolimus Demonstrates Superimposable Anti-tumour Potency on Prostate Cancer Cells. Basic and Clinical Pharmacology and Toxicology, 2013, 112, 63-69.	2.5	15
139	New Agents and Approaches for Targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR Cell Survival Pathways. , 2013, , 331-372.		1
140	Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment. Advances in Biological Regulation, 2013, 53, 146-155.	2.7	14
141	Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia. Expert Opinion on Therapeutic Targets, 2013, 17, 921-936.	3.4	15
142	Nuclear phospholipase C β 1 signaling, epigenetics and treatments in MDS. Advances in Biological Regulation, 2013, 53, 2-7.	2.7	33
143	Inhibition of Cdk2 activity decreases Aurora-A kinase centrosomal localization and prevents centrosome amplification in breast cancer cells. Oncology Reports, 2013, 29, 1785-1788.	2.6	19
144	Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients. Cell Cycle, 2013, 12, 1815-1816.	2.8	4

#	ARTICLE	IF	CITATIONS
145	No-Modified Saquinavir is Equally Efficient Against Doxorubicin Sensitive and Resistant Non-Small Cell Lung Carcinoma Cells / MODIFIKOVANA KOVANA FORMA SAKVINAVIRA EFIKASNO SU PRIMI RA RAST AĀELIJA NESITNOAĀELIJSKOG KARCINOMA PLUAĀA RAZLIAĀEITE OSETUIVOSTI NA DOKSORUBICIN. Journal of Medical Biochemistry, 2013, 32, 406-416.	1.8	2
146	Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells. PLoS ONE, 2013, 8, e65569.	2.5	35
147	The AKT Inhibitor MK-2206 is Cytotoxic in Hepatocarcinoma Cells Displaying Hyperphosphorylated AKT-1 and Synergizes with Conventional Chemotherapy. Oncotarget, 2013, 4, 1496-1506.	1.9	49
148	Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (Review). International Journal of Oncology, 2012, 40, 639-44.	3.1	83
149	Nuclear PI-PLC $\hat{2}$ 1 and Myelodysplastic Syndromes: Genetics and Epigenetics. Current Pharmaceutical Design, 2012, 18, 1751-1754.	1.8	9
150	Molecular Targeted Therapy in Melanoma: A Way to Reverse Resistance to Conventional Drugs. Current Drug Delivery, 2012, 9, 17-29.	1.7	22
151	BRAF mutations in papillary thyroid carcinoma and emerging targeted therapies (Review). Molecular Medicine Reports, 2012, 6, 687-694.	2.4	25
152	Raf-1 oncogenic signaling is linked to activation of mesenchymal to epithelial transition pathway in metastatic breast cancer cells. International Journal of Oncology, 2012, 40, 1858-64.	3.1	24
153	Therapeutic Potential of Nitric Oxide-Modified Drugs in Colon Cancer Cells. Molecular Pharmacology, 2012, 82, 700-710.	2.3	28
154	Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for aœverticalaœand aœlateralœ combination strategies. Journal of Molecular Medicine, 2012, 90, 1133-1144.	4.0	36
155	Novel approaches to target cancer initiating cellsaœEliminating the root of the cancer. Advances in Biological Regulation, 2012, 52, 249-264.	2.7	13
156	Revisiting nuclear phospholipase C signalling in MDS. Advances in Biological Regulation, 2012, 52, 2-6.	2.7	20
157	PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: New options for targeted therapy. Advances in Biological Regulation, 2012, 52, 214-227.	2.7	23
158	The novel NF- \hat{B} inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. Cancer Letters, 2012, 322, 35-44.	7.3	30
159	Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies. Expert Opinion on Therapeutic Targets, 2012, 16, 729-742.	3.4	37
160	Targeting the Cancer Initiating Cell: The Ultimate Target for Cancer Therapy. Current Pharmaceutical Design, 2012, 18, 1784-1795.	1.8	40
161	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. Oncotarget, 2012, 3, 1068-1111.	1.9	281
162	Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.. Oncotarget, 2012, 3, 954-987.	1.9	248

#	ARTICLE	IF	CITATIONS
163	Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. <i>Oncotarget</i> , 2012, 3, 236-260.	1.9	154
164	The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. <i>Journal of Molecular Medicine</i> , 2012, 90, 667-679.	4.0	54
165	Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. <i>Oncotarget</i> , 2012, 3, 371-394.	1.9	109
166	Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels. <i>Oncotarget</i> , 2012, 3, 811-823.	1.9	60
167	Effects of Ectopic Expression of NGAL on Doxorubicin Sensitivity. <i>Oncotarget</i> , 2012, 3, 1236-1245.	1.9	13
168	A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. <i>Oncotarget</i> , 2012, 3, 1615-1628.	1.9	54
169	Advances in Targeting Signal Transduction Pathways. <i>Oncotarget</i> , 2012, 3, 1505-1521.	1.9	41
170	Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes. <i>Oncotarget</i> , 2012, 3, 1522-1532.	1.9	24
171	The mechanism of contribution of integrin linked kinase (ILK) to epithelial-mesenchymal transition (EMT). <i>Advances in Enzyme Regulation</i> , 2011, 51, 195-207.	2.5	43
172	mTOR as a multifunctional therapeutic target in HIV infection. <i>Drug Discovery Today</i> , 2011, 16, 715-721.	6.6	91
173	Targeting the cancer initiating cell: The Achilles' heel of cancer. <i>Advances in Enzyme Regulation</i> , 2011, 51, 152-162.	2.5	16
174	Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. <i>Journal of Cellular Physiology</i> , 2011, 226, 822-831.	4.1	61
175	Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. <i>Journal of Cellular Physiology</i> , 2011, 226, 2762-2781.	4.1	151
176	COX-2-Dependent and COX-2-Independent Mode of Action of Celecoxib in Human Liver Cancer Cells. <i>OMICS A Journal of Integrative Biology</i> , 2011, 15, 383-392.	2.0	28
177	Nuclear phosphoinositides and their roles in cell biology and disease. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2011, 46, 436-457.	5.3	30
178	Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. <i>Aging</i> , 2011, 3, 192-222.	2.8	543
179	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health. <i>Oncotarget</i> , 2011, 2, 135-164.	1.9	517
180	Exploiting p53 Status to Enhance Effectiveness of Chemotherapy by Lowering Associated Toxicity. <i>Oncotarget</i> , 2011, 2, 109-112.	1.9	17

#	ARTICLE	IF	CITATIONS
181	Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy. <i>Oncotarget</i> , 2011, 2, 538-550.	1.9	74
182	Cooperative Effects of Akt-1 and Raf-1 on the Induction of Cellular Senescence in Doxorubicin or Tamoxifen Treated Breast Cancer Cells. <i>Oncotarget</i> , 2011, 2, 610-626.	1.9	42
183	New Perspectives in HCV Therapy: Entry Inhibitors. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2010, 5, 181-194.	1.3	2
184	Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells. <i>Advances in Enzyme Regulation</i> , 2010, 50, 285-307.	2.5	41
185	The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2010, 1803, 991-1002.	4.1	107
186	Induction of caspase-independent apoptotic-like cell death of mouse mammary tumor TA3Ha cells in vitro and reduction of their lethality in vivo by the novel chemotherapeutic agent GIT-27NO. <i>Free Radical Biology and Medicine</i> , 2010, 48, 1090-1099.	4.5	10
187	Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia. <i>Cancer Research</i> , 2010, 70, 8097-8107.	0.9	154
188	The Emerging Role of the Phosphatidylinositol 3-Kinase/ Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology. <i>Cancers</i> , 2010, 2, 1576-1596.	3.8	40
189	The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. <i>Oncotarget</i> , 2010, 1, 89-103.	1.9	230
190	COMMENTARY. Regulation of Drug and Immune Resistance by YY1 in Cancer. <i>Onco Therapeutics</i> , 2010, 1, 149-151.	0.2	0
191	Rationale for Targeting of YY1 in Drug-resistant Leukemias. <i>Onco Therapeutics</i> , 2010, 1, 65-79.	0.2	1
192	Antitumor Effects of Dehydroxymethylepoxyquinomicin, a Novel Nuclear Factor- κ B Inhibitor, in Human Liver Cancer Cells Are Mediated through a Reactive Oxygen Species-Dependent Mechanism. <i>Molecular Pharmacology</i> , 2009, 76, 290-300.	2.3	47
193	The involvement of CaM-KII in insulin induced cell proliferation. <i>Cell Cycle</i> , 2009, 8, 1979-1983.	2.8	3
194	The Role of Downstream Signaling Pathways of the Epidermal Growth Factor Receptor for Artesunates Activity in Cancer Cells. <i>Current Cancer Drug Targets</i> , 2009, 9, 72-80.	1.7	43
195	Emerging Raf inhibitors. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 633-648.	2.4	33
196	PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches. <i>Cell Cycle</i> , 2009, 8, 1352-1358.	2.8	181
197	Melanoma: Molecular pathogenesis and emerging target therapies (Review). <i>International Journal of Oncology</i> , 2009, 34, 1481-9.	3.1	64
198	Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs. <i>Prostate</i> , 2009, 69, 1448-1459.	2.3	75

#	ARTICLE	IF	CITATIONS
199	The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1169-1178.	3.7	39
200	Signaling Intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK Pathways) as Therapeutic Targets for Anti-Cancer and Anti-Angiogenesis Treatments. <i>Current Signal Transduction Therapy</i> , 2009, 4, 130-143.	0.5	11
201	Parallel Signaling through PI3K/AKT/mTOR Mediates Resistance to MEK Inhibition in Preclinical Models of Acute Myeloid Leukemia (AML): Synergistic Effects of Combined MEK and mTOR Inhibition.. <i>Blood</i> , 2009, 114, 594-594.	1.4	0
202	Simultaneous Targeting of Bcl-2/Bcl-Xl and MEK/ERK Results in Highly Synergistic Induction of Apoptosis in Human AML, Both in Vitro and In Vivo.. <i>Blood</i> , 2009, 114, 2757-2757.	1.4	0
203	Dual Inhibition of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin with NVP-BEZ235 as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2009, 114, 2025-2025.	1.4	0
204	Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. <i>Advances in Enzyme Regulation</i> , 2008, 48, 113-135.	2.5	21
205	Akt as a therapeutic target in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 1139-1165.	3.4	131
206	Targeting prostate cancer based on signal transduction and cell cycle pathways. <i>Cell Cycle</i> , 2008, 7, 1745-1762.	2.8	90
207	PKR Regulates B56-mediated BCL2 Phosphatase Activity in Acute Lymphoblastic Leukemia-derived REH Cells. <i>Journal of Biological Chemistry</i> , 2008, 283, 35474-35485.	3.5	45
208	Proapoptotic Activity and Chemosensitizing Effect of the Novel Akt Inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan-2-amine (A443654) in T-Cell Acute Lymphoblastic Leukemia. <i>Molecular Pharmacology</i> , 2008, 74, 884-895.	2.3	33
209	GSK-3 β is a critical mediator of tetrandrine induced cell cycle arrest and cytotoxicity. <i>Cancer Biology and Therapy</i> , 2008, 7, 1079-1079.	3.6	8
210	PI-103, a Dual Inhibitor of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin, Has Cytotoxic Activity in T-Cell Acute Lymphoblastic Leukemia Cells: A New Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2008, 112, 1921-1921.	1.4	1
211	Targeting Survival Cascades Induced by Activation of Ras/Raf/MEK/ERK and PI3K/Akt Pathways to Sensitize Cancer Cells to Therapy. , 2008, , 81-114.		2
212	Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells-a Novel Therapeutic Approach for Leukemia Displaying Elevated Akt Signaling.. <i>Blood</i> , 2008, 112, 957-957.	1.4	10
213	Roles of Raf/MEK/ERK and PI3K/Akt/mTOR Signaling and p53 Pathways on Apoptosis, Drug Resistance and Therapeutic Sensitivity of Early Hematopoietic Precursor Cells. <i>Blood</i> , 2008, 112, 503-503.	1.4	0
214	Development of Mek inhibition (MEK-I)-Based Therapeutic Strategies in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2008, 112, 860-860.	1.4	1
215	The Glycogensynthase Kinase 3b (GSK-3 β) Is Involved in Leukemic Transformation. <i>Blood</i> , 2008, 112, 4489-4489.	1.4	0
216	Erucylphosphocholine, the First Intravenously Applicable Alkylphosphocholine, Induces Cell Cycle Arrest, Apoptosis, and Synergizes with Chemotherapeutic Drugs in Acute Myelogenous Leukemia Cells-a Novel Therapeutic Approach for Leukemia.. <i>Blood</i> , 2008, 112, 1330-1330.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Targeting the PI3K and MAPK pathways to treat Kaposi's sarcoma-associated herpes virus infection and pathogenesis. Expert Opinion on Therapeutic Targets, 2007, 11, 589-599.	3.4	20
218	Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway. Cancer Biology and Therapy, 2007, 6, 1176-1181.	3.6	13
219	Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resistance Updates, 2007, 10, 81-100.	14.6	74
220	PI3K activation is associated with intracellular sodium/iodide symporter protein expression in breast cancer. BMC Cancer, 2007, 7, 137.	2.6	40
221	Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 1263-1284.	4.1	1,901
222	Targeting the RAF/MEK/ERK, PI3K/AKT and P53 pathways in hematopoietic drug resistance. Advances in Enzyme Regulation, 2007, 47, 64-103.	2.5	78
223	Comparative Gene Profiling of Acute Myeloid Leukemia (AML) and Malignant Melanoma (MEL) Cell Lines Exposed to the MEK Inhibitor PD0325901 Reveals Common Effectors of the MEK/ERK Kinase Module.. Blood, 2007, 110, 3470-3470.	1.4	1
224	The Novel Akt Inhibitor Perifosine Induces Apoptosis, Cell Cycle Arrest and Synergizes with Chemotherapeutic Drugs in Acute Myelogenous Leukemia Cells by a JNK Dependent Mechanism - A Novel Therapeutic Approach for Leukemia Displaying Elevated Akt Signaling.. Blood, 2007, 110, 3355-3355.	1.4	0
225	The AKT Inhibitor, A443654, Induces Cell Cycle Arrest, Apoptosis and Synergizes with Chemotherapeutic Drugs in Multi-Drug Resistant T-Cell Acute Lymphoblastic Leukemia - A Novel Agent for Therapy of Drug Resistant ALL.. Blood, 2007, 110, 3344-3344.	1.4	1
226	Roles of Raf/MEK/ERK and PI3K/Akt/mTOR Pathways in Prevention of Apoptosis and Induction of Drug Resistance in Myeloid Hematopoietic Cells.. Blood, 2007, 110, 641-641.	1.4	0
227	Mutations in the Catalytic Subunit of Class IA PI3K Are Leukemogenic In Vivo.. Blood, 2007, 110, 875-875.	1.4	0
228	Reactive Oxygen Intermediates and Signaling Through Kinase Pathways. Antioxidants and Redox Signaling, 2006, 8, 1745-1748.	5.4	26
229	Reactive Oxygen Species-Induced Activation of the MAP Kinase Signaling Pathways. Antioxidants and Redox Signaling, 2006, 8, 1775-1789.	5.4	702
230	Molecular Pathways Leading to Oxidative Stress-Induced Phosphorylation of Akt. Antioxidants and Redox Signaling, 2006, 8, 1749-1756.	5.4	41
231	Intracellular Signaling in Cancer. , 2006, , .		0
232	Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Advances in Enzyme Regulation, 2006, 46, 249-279.	2.5	593
233	Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell, 2006, 10, 375-388.	16.6	933
234	Analysis of TIMP-1 Gene Polymorphisms in Italian Sclerodermic Patients. Journal of Clinical Laboratory Analysis, 2006, 20, 173-176.	2.1	21

#	ARTICLE	IF	CITATIONS
235	Detection of <i>BRAF</i> gene mutation in primary choroidal melanoma tissue. <i>Cancer Biology and Therapy</i> , 2006, 5, 225-227.	3.6	35
236	Absence of BRAF Gene Mutation in Non-Melanoma Skin Tumors. <i>Cell Cycle</i> , 2006, 5, 968-970.	2.8	27
237	Activation of the Calcium/Calmodulin-Dependent Protein Kinases as a Consequence of Oxidative Stress. <i>Antioxidants and Redox Signaling</i> , 2006, 8, 1807-1817.	5.4	47
238	Critical Roles of the Raf/MEK/ERK Pathway in Apoptosis and Drug Resistance. , 2006, , 101-134.		2
239	Mutations of the Catalytic Subunit of Class IA PI3K Are Constitutively Active and Confer Factor-Independent Growth to Early Hematopoietic Cells.. <i>Blood</i> , 2006, 108, 1455-1455.	1.4	0
240	Dominant Role of Raf/MEK/ERK Signaling in Hematopoietic Cell Cycle Progression, Prevention of Apoptosis and Drug Resistance.. <i>Blood</i> , 2006, 108, 1116-1116.	1.4	1
241	B-Raf dependent expression of vascular endothelial growth factor A in Kaposi sarcoma-associated herpesvirus-infected human B cells. <i>Blood</i> , 2005, 105, 4516-4522.	1.4	45
242	Inhibition of CREB transcriptional activity in human T lymphocytes by oxidative stress. <i>Free Radical Biology and Medicine</i> , 2005, 38, 1653-1661.	4.5	10
243	Biology of Kaposi's sarcoma-associated herpesvirus. <i>Frontiers in Bioscience - Landmark</i> , 2005, 10, 2882.	3.1	10
244	Solubility and Bioactivity of the Pseudomonas Quinolone Signal Are Increased by a Pseudomonas aeruginosa-Produced Surfactant. <i>Infection and Immunity</i> , 2005, 73, 878-882.	2.3	81
245	Elevated serum levels of osteopontin in HCV-associated lymphoproliferative disorders. <i>Cancer Biology and Therapy</i> , 2005, 4, 1192-1194.	3.6	27
246	Upping the bid on engineered inducible cell death.. <i>Cancer Biology and Therapy</i> , 2005, 4, 537-537.	3.6	0
247	Modulation of Raf/MEK/ERK kinase activity does not affect the chemoresistance profile of advanced prostate cancer cells. <i>International Journal of Oncology</i> , 2005, 26, 1637.	3.1	8
248	Analysis of BRAF Mutation in Primary and Metastatic Melanoma. <i>Cell Cycle</i> , 2005, 4, 1382-1384.	2.8	92
249	Calcium/calmodulin-dependent protein kinases as potential targets in cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2005, 9, 791-808.	3.4	36
250	The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it?. <i>Expert Opinion on Therapeutic Targets</i> , 2005, 9, 1009-1030.	3.4	47
251	Cigarette smoke concentrate inhibits Kaposi's sarcoma-associated herpesvirus infection. <i>Virus Research</i> , 2005, 114, 172-176.	2.3	10
252	Key Roles of the Raf-1 and Akt in Drug Resistance, Cell Cycle Progression and the Prevention of Apoptosis in Hematopoietic Cells.. <i>Blood</i> , 2005, 106, 1356-1356.	1.4	0

#	ARTICLE	IF	CITATIONS
253	Role of BRAF Mutations in Hematopoietic Malignancies and the Induction of Cytokine-Independence-Synergy with PI3K/Akt Pathway.. Blood, 2005, 106, 4291-4291.	1.4	0
254	Signaling through 3'5'-Cyclic Adenosine Monophosphate and Phosphoinositide-3 Kinase Induces Sodium/Iodide Symporter Expression in Breast Cancer. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5196-5203.	3.6	27
255	Raf-Induced Vascular Endothelial Growth Factor Augments Kaposi's Sarcoma-Associated Herpesvirus Infection. Journal of Virology, 2004, 78, 13381-13390.	3.4	24
256	Role for Raf in the entry of viruses associated with AIDS (Review). International Journal of Oncology, 2004, 25, 469.	3.1	1
257	Vascular endothelial growth factor augments human herpesvirus-8 (HHV-8/KSHV) infection. Cancer Biology and Therapy, 2004, 3, 876-881.	3.6	22
258	Redox Regulation of the Calcium/Calmodulin-dependent Protein Kinases. Journal of Biological Chemistry, 2004, 279, 44573-44581.	3.5	117
259	The complexity of PTEN: mutation, marker and potential target for therapeutic intervention. Expert Opinion on Therapeutic Targets, 2004, 8, 537-550.	3.4	89
260	Raf promotes human herpesvirus-8 (HHV-8/KSHV) infection. Oncogene, 2004, 23, 5227-5241.	5.9	40
261	Integrin signaling links protein kinase C δ to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells. Oncogene, 2004, 23, 8659-8672.	5.9	49
262	Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells. Oncogene, 2004, 23, 7810-7820.	5.9	19
263	A Novel Ring-Substituted Diindolylmethane 1,1-bis [3-(5-methoxyindolyl)]-1-(p-t-butylphenyl) Methane Abrogates ERK Activation and Induces Apoptosis in Acute Myeloid Leukemia (AML).. Blood, 2004, 104, 3399-3399.	1.4	0
264	Fibroblastic, Hematopoietic, and Hormone Responsive Epithelial Cell Lines and Culture Conditions for Elucidation of Signal Transduction and Drug Resistance Pathways by Gene Transfer. , 2003, 218, 185-202.		0
265	Elucidation of Signal Transduction Pathways by Transfection of Cells with Modified Oncogenes. , 2003, 218, 203-220.		0
266	Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. Oncogene, 2003, 22, 2478-2492.	5.9	95
267	Models of Anergy in the Human Jurkat T Cell Line. Assay and Drug Development Technologies, 2003, 1, 537-544.	1.5	10
268	A New Hope for Treatment of Glioblastomas. Cancer Biology and Therapy, 2003, 2, 354-355.	3.6	0
269	EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). International Journal of Oncology, 2003, 22, 237.	3.1	50
270	Enhanced ability of the progenipoietin-1 to suppress apoptosis in human hematopoietic cells. International Journal of Molecular Medicine, 2002, 10, 385.	4.0	2

#	ARTICLE	IF	CITATIONS
271	The Effects of Beta-Estradiol on Raf Activity, Cell Cycle Progression and Growth Factor Synthesis in the MCF-7 Breast Cancer Cell Line. <i>Cancer Biology and Therapy</i> , 2002, 1, 256-262.	3.6	28
272	Participation of the Calcium/Calmodulin-dependent Kinases in Hydrogen Peroxide-induced I β B Phosphorylation in Human T Lymphocytes. <i>Journal of Biological Chemistry</i> , 2002, 277, 30469-30476.	3.5	54
273	Raf-Induced Cell Cycle Progression in Human TF-1 Hematopoietic Cells. <i>Cell Cycle</i> , 2002, 1, 218-224.	2.8	29
274	Targeting the Raf kinase cascade in cancer therapy – novel molecular targets and therapeutic strategies. <i>Expert Opinion on Therapeutic Targets</i> , 2002, 6, 659-678.	3.4	27
275	Synergistic effects of pi3k/akt on abrogation of cytokine-dependency induced by oncogenic raf. <i>Advances in Enzyme Regulation</i> , 2001, 41, 289-323.	2.5	23
276	P21Cip1 induced by Raf is associated with increased Cdk4 activity in hematopoietic cells. <i>Oncogene</i> , 2001, 20, 4354-4364.	5.9	45
277	A conditionally-active form of MEK1 results in autocrine transformation of human and mouse hematopoietic cells. <i>Oncogene</i> , 2000, 19, 526-536.	5.9	78
278	The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors. , 2000, 88, 229-279.		86
279	Calcium-induced ERK activation in human T lymphocytes occurs via p56Lck and CaM-kinase. <i>Molecular Immunology</i> , 2000, 37, 675-683.	2.4	57
280	Effects of deregulated RAF and MEK1 expression on the cytokine-dependency of hematopoietic cells. <i>Advances in Enzyme Regulation</i> , 2000, 40, 305-337.	2.5	24
281	Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. <i>Journal of Immunological Methods</i> , 1993, 157, 233-240.	1.4	309
282	Structure and expression of the T cell receptor gamma locus in pre-B and early hemopoietic cells. <i>European Journal of Immunology</i> , 1989, 19, 2303-2308.	3.3	12
283	Transfer of specificity by murine I α and I β T-cell receptor genes. <i>Nature</i> , 1986, 320, 232-238.	35.8	583
284	Transformation of B and non-B cell lines with the 2,4,6- trinitrophenyl (TNP)-specific immunoglobulin genes. <i>European Journal of Immunology</i> , 1985, 15, 1117-1124.	3.3	13
285	Activation of Nonexpressed Endogenous Ecotropic Murine Leukemia Virus by Transfection of Genomic DNA into Embryo Cells. <i>Journal of Virology</i> , 1983, 45, 950-955.	3.4	6
286	Genetic interactions in induction of endogenous murine leukemia virus from low leukemic mice. <i>Cell</i> , 1982, 28, 881-888.	27.7	35
287	Combining chemo-, hormonal and targeted therapies to treat breast cancer (Review). <i>Molecular Medicine Reports</i> , 0, , .	2.4	3